Mood Disorders

Bipolar depression does not have a single face. Through one patient’s journey, this case-based reflection explores 5 distinct presentations and how each can shape clinical recognition and treatment.

From tricyclics to esketamine, Ron Pies, MD, explains antidepressant progress and why precise diagnosis matters when treating today’s diverse depression.

Psychiatrists rebut antidepressant myths, outlining modest benefits, real but manageable risks, and why slow tapering matters for withdrawal.

Learn how clinicians manage bipolar disorder in women who may become pregnant—safer meds, contraception counseling, and relapse prevention.

COMP360 psilocybin shows rapid, durable gains in treatment‑resistant depression, as psychedelics continue to grow.

Where can vagus nerve stimulation fit into treating depression?

Phase 3 COMP360 psilocybin data show lasting TRD relief; experts explain brain-network reset, therapy support, and what approval could mean.

Learn about screening for postpartum depression and available pharmacological treatments.

Consensus guidance clarifies IV ketamine dosing, monitoring, staffing and consent to support safer, evidence-based depression treatment.

Explore how to manage mood and substance use disorders together, boost engagement, and expand addiction medications.

New data suggest seltorexant may ease insomnia in MDD while limiting weight gain and potentially improving metabolic risk factors.

Phase 3 data show adjunctive seltorexant eases depression and insomnia with lessened weight gain and somnolence.

Sleep and circadian rhythm disruption shape psychiatric symptoms and bipolar mood shifts.

Explore the intersections of bipolar disorder with clinical trials and AI.

Once-nightly regular-release lithium cuts kidney risk, maintains bipolar control, improves adherence, and guides safer serum levels.

Phase 2 depression trial shows ALTO-203 boosts attention, EEG theta-beta ratio and alertness, pointing to biomarker-guided dosing and precision psychiatry.

Expert analysis compares adjunctive atypical antipsychotics for MDD, highlighting lumatperone’s larger effect and minimal weight gain or akathisia.

Yale psychiatrists test esketamine vs IV ketamine for resistant depression, probing long-term safety, side effects, and misuse in real-world care.

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.

Luvesilocin enters phase 2, hinting at lasting relief after 1–2 doses and a new 5-HT2A model.

Investigational depression drugs target SIRT6 epigenetics, histamine H3, and AMPA.

Psychiatrist Gus Alva highlights new depression therapies, neuromodulation, and why screening for bipolar disorder prevents antidepressant harm.

Learn why insomnia and daytime sleepiness signal psychiatric risk, and how screening for apnea, delayed phase, and fatigue sharpens treatment.

Learn more about strategies for deprescribing, and the importance of finding the most effective medication possible.

Real-world registry data reveals young adults with mood disorders face high TD burden yet low diagnosis rates, spotlighting urgent screening gaps.